Eli Lilly

Eli Lilly is the largest pharmaceutical company on earth by market cap — $862B as of May 12, 2026 — and the single most spectacular revenue-growth story in the S&P 500 for the past three years. Q1/2026 revenue: $14.9B, +55% YoY. Mounjaro (Type-2 diabetes GLP-1) generated $5.8B in Q1 alone, Zepbound (weight-loss GLP-1) added $3.9B. Together they represent 65% of Lilly's revenue and are still supply-constrained — manufacturing capacity remains the bottleneck rather than demand.

The capital expenditure story is unique in pharma history. Lilly has committed $50B+ in manufacturing capacity expansion through 2028 — including new plants in Indiana ($9B), Ireland ($8B), North Carolina ($5B), and Germany ($2.3B). The Q1/2026 capex run-rate of $8.4B is the highest in pharma-industry history. The reason: management forecasts $80B+ in GLP-1 revenue alone by 2030, and that requires the manufacturing capacity to be built today.

The competitive picture is bifurcating. Novo Nordisk (the only meaningful GLP-1 competitor with Ozempic/Wegovy) lost market share for the fourth consecutive quarter in Q1/2026. Zepbound's efficacy advantage (-22.5% body weight at 72 weeks in SURMOUNT-5 vs. Wegovy's -15%) plus a more favorable cardiovascular outcome profile is widening the gap. The pipeline behind that is real: retatrutide (triple-agonist) showed -24.2% in Phase 2 and is expected to launch in 2027.

Eli Lilly's institutional ownership tilted toward growth-momentum hands during the 2023–2025 GLP-1 supercycle. Generation Investment Management (Al Gore) holds 4.2M shares — their largest healthcare position. Capital Group remains the largest active holder at 22.4M shares (Form 13F Q1/2026). The notable buyer in 2026 is Public Investment Fund of Saudi Arabia, which initiated a $1.8B position in Q1/2026 — a sovereign-wealth bet on the GLP-1 secular trend.

The notable absence: Berkshire Hathaway has never held Lilly. Buffett historically avoids pharma (Cardinal Health and DaVita are the exceptions) due to patent-cliff risk. Berkshire's absence is the cleanest signal that smart-money value investors do not view current LLY valuation as compelling — which is independent of whether the GLP-1 story is real.

Insider activity (Form 4): CEO David Ricks sold 96,000 shares between January and April 2026 at an average of $940 (10b5-1 plan). CFO Anat Ashkenazi sold 28,000 shares in February. No insider buys in the past 24 months — typical for a high-growth pharma where the stock has been at all-time highs. The pattern is consistent with management view that current valuation reflects the GLP-1 opportunity fairly.

Eli Lilly trades at a forward P/E of 21.8, EV/Sales of 14.4, and EV/EBITDA of 32 as of May 2026. Comparable mega-cap pharma — Novo Nordisk (forward P/E 17, EV/Sales 13), Merck (forward P/E 12.4), and Roche (forward P/E 14) — trade at meaningful discounts to Lilly. The premium reflects the GLP-1 growth trajectory: Lilly's 5-year revenue CAGR is projected at 28%, versus 8% for Merck and 4% for Roche. The forward PEG ratio of ~0.40 is below 1.0, which historically marks attractive growth-at-a-reasonable-price entry. Wall Street median price target $1209 (25% upside), with dispersion from $890 (Cantor Fitzgerald, pricing-pressure bear) to $1450 (Berenberg, full-pipeline-success bull). Sum-of-the-parts: GLP-1 franchise (Mounjaro + Zepbound at peak $80B revenue) discounted to today at $610/share, oncology + immunology at $180/share, pipeline optionality (retatrutide, orforglipron, donanemab) at $220/share — total $1010/share intrinsic, ~5% above current.

1. August 7, 2026: Q2/2026 earnings — net price and supply-availability metrics on Zepbound/Mounjaro are the key prints
2. Q3/2026: Orforglipron (oral GLP-1) Phase 3 readout — successful = adds $20B TAM, miss = thesis crack
3. Q4/2026: SURPASS-CVOT cardiovascular outcomes readout and retatrutide Phase 3 — two binary events that frame 2027–2030

Eli Lilly is one of the few pharma stocks I genuinely consider holding for the long term, but I do not own it at current prices. The GLP-1 story is the most important pharmaceutical commercial story of the 2020s, and Lilly has a 2–3 year manufacturing-capacity lead over Novo Nordisk that is genuinely durable. The 21.8× forward P/E is reasonable for the growth trajectory — but it requires the pipeline to keep delivering. Two binary events in late 2026 (orforglipron and SURPASS-CVOT) will determine whether the multiple expands toward 28× or compresses toward 16×. The asymmetric setup heading into those reads suggests waiting. My add-trigger is below $850 (sub-19× forward) which gives me margin of safety for the binary events, or a positive orforglipron print followed by a buy regardless of price. For now, watch.